BofA analyst Jason Gerberry raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $85 from $80 and keeps a Buy rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential